JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

JNJ

233.45

+2.12%↑

ISRG

491.45

-1.68%↓

ABT

108.22

-2.08%↓

RDY

13.8

+4.94%↑

NEOG

10.82

+4.84%↑

Search

AngioDynamics Inc

Abierto

SectorSanidad

10.5 1.74

Resumen

Variación precio

24h

Actual

Mínimo

10.27

Máximo

10.56

Métricas clave

By Trading Economics

Ingresos

4.6M

-6.4M

Ventas

3.7M

79M

Margen de beneficios

-7.994

Empleados

675

EBITDA

4.4M

-436K

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+86.58% upside

Dividendos

By Dow Jones

Próximas Ganancias

1 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-119M

426M

Apertura anterior

8.76

Cierre anterior

10.5

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

147 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

AngioDynamics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 feb 2026, 23:52 UTC

Adquisiciones, fusiones, absorciones

Elliott Management Doesn't Plan to Tender Its Shares at the Current Terms

2 feb 2026, 23:52 UTC

Adquisiciones, fusiones, absorciones

Elliott Management: Toyota Fudosan Revised Tender Offer for Toyota Industries 'Very Significantly Undervalues' Company

2 feb 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

2 feb 2026, 23:38 UTC

Charlas de Mercado

Gold Rises on Likely Technical Recovery, Dip-Buying Interest -- Market Talk

2 feb 2026, 23:28 UTC

Charlas de Mercado

SpaceX, xAI Deal Further Consolidates Musk's Businesses -- Market Talk

2 feb 2026, 23:23 UTC

Ganancias

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- 2nd Update

2 feb 2026, 22:57 UTC

Ganancias

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

What the Blockbuster SpaceX--xAI Merger Can Mean for Tesla Stock -- Barrons.com

2 feb 2026, 22:08 UTC

Charlas de Mercado

Australian Inflation Woes Rooted In Excess Govt Spending -- Market Talk

2 feb 2026, 21:51 UTC

Ganancias

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 feb 2026, 21:49 UTC

Ganancias

Disney's Streaming Profit Surges as CEO Decision Approaches -- 5th Update

2 feb 2026, 21:39 UTC

Ganancias

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:36 UTC

Ganancias

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- Update

2 feb 2026, 21:34 UTC

Ganancias

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:28 UTC

Adquisiciones, fusiones, absorciones

What a SpaceX--xAI Merger Could Mean for Tesla Stock -- Barrons.com

2 feb 2026, 21:23 UTC

Ganancias

BYD, Chinese EV Stock Plunge On Weak Data. What That Means for Tesla Stock. -- Barrons.com

2 feb 2026, 21:19 UTC

Ganancias

Palantir Technologies: U.S. Commercial Business Growing at 'Astonishing' Rate, Generating $507 Million Last Quarter, 137% Increase Over the Same Period the Year Before >PLTR

2 feb 2026, 21:17 UTC

Ganancias

Palantir Achieves Another Revenue Record With $1.41 Billion Quarter -- WSJ

2 feb 2026, 21:17 UTC

Ganancias

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:10 UTC

Ganancias

Palantir Reports Strong Earnings. The Stock Is Rising. -- Barrons.com

2 feb 2026, 21:08 UTC

Ganancias

Palantir Technologies: Rule of 40 Score Is Now 127% >PLTR

2 feb 2026, 21:07 UTC

Ganancias

Palantir Technologies: Sees 2026 U.S. Comml Rev in Excess of $3.144B, Representing Growth Rate of at Least 115% >PLTR

2 feb 2026, 21:05 UTC

Ganancias

Palantir Technologies 4Q Net $608.7M >PLTR

2 feb 2026, 21:05 UTC

Ganancias

Palantir Technologies 4Q Rev $1.41B >PLTR

2 feb 2026, 21:05 UTC

Ganancias

Palantir Technologies Sees 1Q Rev $1.53B-$1.54B >PLTR

2 feb 2026, 21:05 UTC

Ganancias

Palantir Technologies Sees FY Rev $7.18B-$7.2B >PLTR

2 feb 2026, 21:05 UTC

Ganancias

Palantir Technologies 4Q Adj EPS 25c >PLTR

2 feb 2026, 21:05 UTC

Ganancias

Palantir Technologies 4Q EPS 24c >PLTR

2 feb 2026, 20:40 UTC

Charlas de Mercado

Treasury Yields, Dollar Rise Amid Signs of Resilient U.S. Economy -- Market Talk

Comparación entre iguales

Cambio de precio

AngioDynamics Inc previsión

Precio Objetivo

By TipRanks

86.58% repunte

Estimación a 12 Meses

Media 19.33 USD  86.58%

Máximo 24 USD

Mínimo 16 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AngioDynamics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

9 / 9.3Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

147 / 352 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de AngioDynamics Inc

AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
help-icon Live chat